BioSpace News Archive

NEXGEL, Inc. today announced it will report its financial results for the fourth quarter and full year periods ended December 31, 2022, after the market closes on March 27, 2023.

BrainsWay Ltd. today reported fourth quarter and full-year 2022 financial results and provided an operational update.

Zevra Therapeutics today announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”).

Navidea Biopharmaceuticals, Inc. today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter.

Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer and chief transformation officer, will present and participate in an analyst-led fireside chat at the 2023 virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wed., March 22.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (AML) harboring a FMS-like tyrosine kinase mutation (FLT3mut+), at the Massachusetts General Hospital in Boston, US.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of March 2023, which is payable on April 17, 2023 to shareholders of record at the close of business on March 31, 2023.

Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association for Cancer Research (AACR) has accepted an abstract on its Decoy anti-tumor platform for its annual scientific conference on April 14-19, 2023 in Orlando.

Onconova Therapeutics, Inc. today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023.

Statera Biopharma, Inc. is pleased to announce it has entered into a non-binding letter of intent with Worksite Labs, Inc., setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL.